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Background: Tranexamic acid has been reported to be safer with topical administration than with
intravenous administration in total knee arthroplasty. However, the most effective administration route
of tranexamic acid in total hip arthroplasty remains controversial. This study compared the effectiveness
of topical tranexamic acid administration with that of intravenous tranexamic acid administration in
total hip arthroplasty.
Methods: We retrospectively examined the medical records of 886 patients with osteoarthritis of the hip
joint, who had undergone unilateral primary total hip arthroplasty. The patients were divided into a
control group (n¼ 302; did not receive tranexamic acid), topical group (n¼ 265; topically administered 2 g
tranexamic acid in 30 mL normal saline via drain tubes placed in the joint before wound closure along with
posterior soft tissue repair), and intravenous group (n ¼ 319; intravenously administered 1 g tranexamic
acid before skin incision along with posterior soft tissue repair). Data on blood loss, hemoglobin levels,
transfusion rates, and occurrence of deep vein thrombosis and pulmonary embolization were collected.
Results: The mean operation times were approximately 40 min in all of the groups. The operation time
and intra-operative blood loss were signiﬁcantly lower in the control group than in the topical and
intravenous groups. However, the post-operative blood loss, total blood loss, and decrease in the he-
moglobin level were signiﬁcantly higher in the control group than in the topical and intravenous groups.
There were no signiﬁcant differences in terms of blood loss and systemic complications between the
tranexamic acid administration methods.
Conclusions: Tranexamic acid reduces both post-operative and total blood loss in total hip arthroplasty.
Moreover, a lower amount of tranexamic acid can be used to reduce blood loss in total hip arthroplasty
with intravenous tranexamic acid administration than with topical tranexamic acid administration.
Therefore, we suggest that tranexamic acid should be intravenously administered pre-operatively and
the posterior soft tissue should be repaired to decrease total hip arthroplasty-related complications.
© 2015 The Authors. Published by Elsevier B.V. on behalf of The Japanese Orthopaedic Association.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Total hip arthroplasty (THA) is one of the most common or-
thopedic operations for osteoarthritis. However, THA often results
in severe peri-operative blood loss that requires blood transfusion
[1,2], which increases the risk of joint infection [3] and viral
transmission [4,5].: þ81 952 34 2059.
. Ueno).
r B.V. on behalf of The Japanese O
license (http://creativecommons.Skillful procedure will help to avoid these risks. Additionally,
many different blood-conserving techniques, including autologous
blood transfusion [6] and use of autologous ﬁbrin tissue [7], have
been developed to reduce blood loss and post-operative blood
transfusion rates [8].
Tranexamic acid (TXA) is a synthetic antiﬁbrinolytic agent that
has been successfully used to control bleeding in several surgical
ﬁelds. Studies have shown that it reduces blood loss and prevents a
decrease in hemoglobin levels without increasing the risk of deep
vein thrombosis (DVT) in THA [9,10].
TXA can be administered through different routes, including
intramuscular (IM), oral, intravenous (IV), and topical, and eachrthopaedic Association.
org/licenses/by-nc-nd/4.0/).
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(5e15 min for IV injection, 30 min for IM injection, and 2 h for
oral administration [11]). TXA has been reported to be safer
with topical administration than with IV administration in total
knee arthroplasty (TKA) [12]. Many recent studies have reported
that IV TXA administration reduces blood loss in THA
[8,10,13e17], and the efﬁcacy of topical TXA administration in
THA was also investigated [18e21]. However, the most effective
administration route of TXA in THA remains controversial. The
aim of the present study was to compare the effectiveness of
topical TXA administration with that of IV TXA administration in
THA.2. Materials and methods
In this case series, we retrospectively examined the medical
records of 886 patients with osteoarthritis of the hip joint, who had
undergone unilateral primary THA performed by 6 senior surgeons
between August 2009 and March 2013. Patients who had been
administered anticoagulants and antiplatelet drugs pre-operatively
and those with ischemic heart disease, chronic renal failure, a
history of hip surgery, thromboembolic episodes, rheumatoid
arthritis, idiopathic osteonecrosis of the femoral head, or a pre-
operative hemoglobin level below 8 g/dL were excluded. All sur-
geons used the same surgical instruments and standardized oper-
ative method. All THA procedures were performed under spinal
anesthesia, using a posterior approach. Cementless stems and cups
(Kyocera PerFix Total Hip System 910 Series; Kyocera, Osaka, Japan)
and a suction drain were used in all cases. The suction drain was
removed 2 days after the operation.
All patients followed the same clinical pathway, including
standard post-operative care and antithrombotic therapy. Based on
the guidelines for blood transfusion, red blood cells were trans-
fused for symptoms of anemia, including vertigo, hypotension, and
bradycardia.
Laboratory datawere obtained 1e2 days before and 1 and 7 days
after the operation. Blood loss (intra-operative, post-operative, and
total), decrease in the hemoglobin level, and transfusion rates were
recorded. Intra-operative blood loss was determined based on the
contents of the suction bottle and the change in the weight of the
used surgical sponges, while post-operative blood loss was deter-
mined based on the contents of the drain.
The primary outcomes were operation time, blood loss (intra-
operative, post-operative, and total), and decrease in the hemo-
globin level at 1 and 7 days after the operation. The secondary
outcomes were the transfusion rate, DVT, and occurrence of pul-
monary embolization (PE) events.
The patients were divided into the following 3 groups: the
control group (patients who did not receive TXA between August
2009 and September 2010; n ¼ 302), topical group (patients who
received topical TXA administration [2 g] before wound closure
between October 2010 and December 2011; n ¼ 265), and IV group
(patients who received IV TXA administration [1 g] before skinTable 1
Characteristics of patients who had undergone total hip arthroscopy with or without tra
Control group (n ¼ 302)
Age (years) 63.6 ± 9.7
Gender (M:F) 26:276
Body weight (kg) 56.7 ± 10.2
Body mass index (kg/m2) 24.5 ± 4.0
Preoperative hemoglobin level (g/dL) 13.0 ± 1.3
Data are reported as mean ± SD or as the total number.
a Denotes signiﬁcant differences between the control and intravenous groups based oincision between January 2012 and March 2013; n ¼ 319). In the
topical group, TXA was administered with 30 mL normal saline via
the drain tubes. Patients in the topical and IV groups underwent
repair of the capsule of the hip joint and short rotator muscles.
Because the Ministry of Health, Labour and Welfare in Japan limits
IV TXA administration to a maximum of 1 g in a single dose, we
used 2 different doses for IV (1 g) and topical (2 g) administration.
The groups were compared using the KruskaleWallis test and chi-
square test. All statistical analyses were performed using SPSS
Version 21 for Windows (IBM Corp, Armonk, NY). A p-value <0.05
was considered signiﬁcant.
The institutional review board approved this study, and the
requirement for informed consent was waived owing to the
retrospective nature of the study.
3. Results
The control, topical, and IV groups included 302, 265, and 319
patients, respectively. Regarding the patient characteristics, no
statistically signiﬁcant differences were noted in height, weight,
body mass index, and pre-operative hemoglobin level between the
groups. However, the age of the patients was lower in the control
group than in the IV group (Table 1).
The mean operation times were approximately 40 min in all of
the groups. The operation time and intra-operative blood loss were
signiﬁcantly lower in the control group than the topical and IV
groups (Table 2). However, the post-operative blood loss, total
blood loss, and decrease in the hemoglobin level were signiﬁcantly
higher in the control group than in the topical and IV groups. There
were no signiﬁcant differences in blood loss (intra-operative, post-
operative, and total) and hemoglobin levels between the topical
and IV groups.
Because the age of the patients was low in the control group,
linear regression analyses were performed to determine the po-
tential relationships of the variables with age. We found that the
relationship between age and operation time, blood loss, or change
in the hemoglobin level was not signiﬁcant.
There were no statistically signiﬁcant differences in transfusion
rates between the groups (Table 3). One case of asymptomatic DVT
was noted in the IV group; however, a symptomatic PE event did
not occur in any of the groups.
4. Discussion
The present study found that TXA reduced both post-operative
and total blood loss in THA. Additionally, no signiﬁcant differ-
ences were noted between the TXA administration methods in
terms of blood loss (intra-operative, post-operative, or total), he-
moglobin levels, transfusion rates, and systemic complications,
despite a difference in the amount of TXA administered between
the topical and IV groups.
The mean operation times were approximately 40 min in all of
the groups, which are remarkably lower than the operation timesnexamic acid administration.
Topical group (n ¼ 265) Intravenous group (n ¼ 319)
64.9 ± 10.5 65.8 ± 9.4a
33:232 46:273
57.5 ± 20.6 57.2 ± 11.3
24.6 ± 3.7 24.4 ± 4.2
13.0 ± 1.2 13.0 ± 1.3
n a KruskaleWallis test.
Table 2
Perioperative outcomes of patients who had undergone total hip arthroscopy with or without tranexamic acid administration.
Control group (n ¼ 302) Topical group (n ¼ 265) Intravenous group (n ¼ 319) p-value
Operation time (min) 39.2 ± 9.1 42.2 ± 8.0a 43.5 ± 9.0a 0.251
Decrease in hemoglobin levels (g/dL)
Day 1 3.2 ± 1.1 1.9 ± 0.8a 1.9 ± 0.9a 1.000
Day 7 3.6 ± 1.4 2.1 ± 0.9a 2.2 ± 0.9a 1.000
Blood loss (g)
Intra-operative 241.1 ± 97.0 278.7 ± 113.0a 290.3 ± 124.1a 0.542
Post-operative 372.2 ± 172.7 240.7 ± 127.1a 252.9 ± 127.8a 0.982
Total 613.3 ± 199.5 519.4 ± 184.6a 560.0 ± 194.7a 0.439
Data are reported as mean ± SD.
The p-value reﬂects the comparison between the topical and intravenous groups.
a Denotes signiﬁcant differences between the control group and intravenous group or topical group based on KruskaleWallis tests.
Table 3
Rates of blood transfusion and incidence of thromboembolic events in patients who had undergone total hip arthroscopy with or without tranexamic acid administration.
Control group (n ¼ 292) Topical group (n ¼ 260) Intravenous group (n ¼ 312)
Blood transfusion 10 (3.3%) 5 (1.9%) 7 (2.2%)
Deep vein thrombosis 0 0 1 (0.5%)
Pulmonary embolism 0 0 0
Data are presented as number (percentage).
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plications and side effects after THA, we standardized the operative
method and shortened the operation time. All surgeons in our
hospital use the same surgical instruments and standardized
operative method. Therefore, we succeeded in improving the THA
technique and the skill of the surgical staff, resulting in reduced
operation durations and lower blood loss in our hospital compared
to those reported in previous studies. To reduce blood loss and the
occurrence of complications even further, we started administering
TXA and repairing the posterior soft tissue to maintain the TXA
close to the surgical site. We found that these modiﬁcations
increased the operation time and the intra-operative blood loss
with both topical and IV administration of TXA. However, repair of
the posterior soft tissue can decrease the risk of dislocation. We
believe that TXA administration and repair of the posterior soft
tissue decreased the occurrence of THA-related complications,
despite the disadvantage of a long operation time.
A previous study reported that TXA is safer with topical
administration than with IV administration in TKA because topical
TXA administration minimizes the occurrence of systemic com-
plications [12]. Furthermore, topical TXA injection has the advan-
tage of inducing partial microvascular hemostasis by inhibiting the
dissolution of ﬁbrin clots in the affected area [22]. However, it is
difﬁcult to compare TKA with THA because TKA is usually per-
formed with a tourniquet, and TXA administered intravenously
does not reach the surgical site.
Although a direct relationship has been reported between the
total amount of TXA administered and post-operative blood loss
[15], in the present study, there were no signiﬁcant differences
between topical TXA administration (2 g) and IV TXA administra-
tion (1 g) in terms of blood loss (intra-operative, post-operative,
and total), despite differences in the amount of TXA adminis-
tered. Therefore, a lower amount of TXA can be used to achieve
appropriate outcomes in THAwith IV TXA administration thanwith
topical TXA administration.
In the present study, ﬁbrinolysis would not have been
completely activated at the end of the operation in the IV group
because the operation time was remarkably shorter in the IV group
than in groups presented in previous study [14]. TXA binds
reversibly to plasminogen and blocks the binding of plasminogen to
ﬁbrin, which activates and transforms plasminogen to plasmin[23]; TXA requires the time for plasminogen to be activated. Dahl
et al. reported that the ﬁbrinolytic response occurs in the early
phases of operative procedures [24], and Imai et al. reported that
TXA reduces intra-operative blood loss [14]. However, because of
the short operation times in the present study, pre-operative TXA
administration could not reduce intra-operative blood loss.
Therefore, if the operation times were long, intra-operative blood
loss would be low with pre-operative TXA administration. IV TXA
administration at the end of the operation has been shown not to
reduce post-operative blood loss in hip arthroplasty [8]. Therefore,
IV TXA administration should be performed pre-operatively.
TXA reduced both post-operative and total blood loss in THA.
Additionally, we found no signiﬁcant differences in blood loss and
systemic complications between the TXA administration methods.
Moreover, a lower amount of TXA can be used to reduce blood loss
in THA with IV TXA administration than with topical TXA admin-
istration. Therefore, we suggest that TXA should be intravenously
administered pre-operatively and the posterior soft tissue should
be repaired to decrease THA-related complications.Conﬂict of interest
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